GB201620119D0 - Compounds - Google Patents

Compounds

Info

Publication number
GB201620119D0
GB201620119D0 GBGB1620119.6A GB201620119A GB201620119D0 GB 201620119 D0 GB201620119 D0 GB 201620119D0 GB 201620119 A GB201620119 A GB 201620119A GB 201620119 D0 GB201620119 D0 GB 201620119D0
Authority
GB
United Kingdom
Prior art keywords
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1620119.6A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmafox Therapeutics AG
Original Assignee
Pharmafox Therapeutics AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmafox Therapeutics AG filed Critical Pharmafox Therapeutics AG
Priority to GBGB1620119.6A priority Critical patent/GB201620119D0/en
Publication of GB201620119D0 publication Critical patent/GB201620119D0/en
Priority to AU2017367277A priority patent/AU2017367277B2/en
Priority to EP17808609.6A priority patent/EP3548509A1/en
Priority to US16/464,969 priority patent/US11407799B2/en
Priority to JP2019548783A priority patent/JP7683901B2/ja
Priority to CN201780073720.2A priority patent/CN110036024B/zh
Priority to CA3045245A priority patent/CA3045245A1/en
Priority to NZ754625A priority patent/NZ754625A/en
Priority to KR1020197018624A priority patent/KR102622245B1/ko
Priority to PCT/IB2017/057436 priority patent/WO2018100483A1/en
Priority to ZA2019/03261A priority patent/ZA201903261B/en
Priority to JP2023083666A priority patent/JP2023116479A/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GBGB1620119.6A 2016-11-29 2016-11-29 Compounds Ceased GB201620119D0 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
GBGB1620119.6A GB201620119D0 (en) 2016-11-29 2016-11-29 Compounds
PCT/IB2017/057436 WO2018100483A1 (en) 2016-11-29 2017-11-28 Muscle performance improvement compounds
JP2019548783A JP7683901B2 (ja) 2016-11-29 2017-11-28 筋肉性能改善化合物
EP17808609.6A EP3548509A1 (en) 2016-11-29 2017-11-28 Muscle performance improvement compounds
US16/464,969 US11407799B2 (en) 2016-11-29 2017-11-28 Muscle performance improvement compounds comprising C-terminus agrin fragment and an ACTR2B inhibitor
AU2017367277A AU2017367277B2 (en) 2016-11-29 2017-11-28 Muscle performance improvement compounds
CN201780073720.2A CN110036024B (zh) 2016-11-29 2017-11-28 肌肉性能改善化合物
CA3045245A CA3045245A1 (en) 2016-11-29 2017-11-28 Muscle performance improvement compounds
NZ754625A NZ754625A (en) 2016-11-29 2017-11-28 Muscle performance improvement compounds
KR1020197018624A KR102622245B1 (ko) 2016-11-29 2017-11-28 근육 성능 개선 화합물
ZA2019/03261A ZA201903261B (en) 2016-11-29 2019-05-23 Muscle performance improvement compounds
JP2023083666A JP2023116479A (ja) 2016-11-29 2023-05-22 筋肉性能改善化合物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1620119.6A GB201620119D0 (en) 2016-11-29 2016-11-29 Compounds

Publications (1)

Publication Number Publication Date
GB201620119D0 true GB201620119D0 (en) 2017-01-11

Family

ID=58073474

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1620119.6A Ceased GB201620119D0 (en) 2016-11-29 2016-11-29 Compounds

Country Status (11)

Country Link
US (1) US11407799B2 (enExample)
EP (1) EP3548509A1 (enExample)
JP (2) JP7683901B2 (enExample)
KR (1) KR102622245B1 (enExample)
CN (1) CN110036024B (enExample)
AU (1) AU2017367277B2 (enExample)
CA (1) CA3045245A1 (enExample)
GB (1) GB201620119D0 (enExample)
NZ (1) NZ754625A (enExample)
WO (1) WO2018100483A1 (enExample)
ZA (1) ZA201903261B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018089706A2 (en) 2016-11-10 2018-05-17 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
WO2019094751A1 (en) 2017-11-09 2019-05-16 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
KR20200109330A (ko) 2018-01-12 2020-09-22 케로스 테라퓨틱스, 인크. 액티빈 수용체 유형 iib 변이체 및 그의 사용 방법
AU2019266314B2 (en) 2018-05-09 2025-05-15 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
WO2021133822A1 (en) 2019-12-24 2021-07-01 Juvena Therapeutics,Inc. Regenerative polypeptides and uses thereof
WO2021189010A1 (en) * 2020-03-20 2021-09-23 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
WO2021189006A1 (en) * 2020-03-20 2021-09-23 Keros Therapeutics, Inc. Methods of using activin receptor type iia variants
WO2022019829A1 (en) * 2020-07-24 2022-01-27 Agency For Science, Technology And Research Wound healing composition and uses thereof
US20250064952A1 (en) * 2021-03-10 2025-02-27 Acceleron Pharma Inc. Actrii-alk4 antagonists and methods of treating heart failure
WO2022192404A1 (en) * 2021-03-10 2022-09-15 Acceleron Pharma Inc. Actrii-alk4 antagonists and methods of treating heart failure
CA3223707A1 (en) 2021-06-21 2022-12-29 Hanadie Yousef Regenerative polypeptides and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2174098C (en) * 1993-10-14 2011-01-25 Douglas A. Melton Method of inducing and maintaining neuronal cells
US20040223966A1 (en) 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
WO2005033134A2 (en) 2003-09-30 2005-04-14 Regeneron Pharmaceuticals, Inc. Secreted protein therapeutics and uses thereof
US20060216279A1 (en) * 2005-03-22 2006-09-28 Glass David J Myostatin inhibiting fusion polypeptides and therapeutic methods thereof
US20100004171A1 (en) 2006-08-08 2010-01-07 Bazan Nicolas G Therapeutic Methods for Neuropathic Pain
KR101123531B1 (ko) 2006-09-05 2012-04-20 일라이 릴리 앤드 캄파니 항-마이오스타틴 항체
KR20200054317A (ko) 2007-02-09 2020-05-19 악셀레론 파마 인코포레이티드 액티빈-ＡｃｔＲⅡＡ 길항제 및 암 환자에서 골 생장을 촉진시키기 위한 이의 용도
ES2655877T3 (es) * 2009-04-27 2018-02-22 Novartis Ag Composiciones y métodos para aumentar el crecimiento muscular
EP2440577A4 (en) 2009-06-12 2013-01-23 Acceleron Pharma Inc SHORTEN ACTRIIB FC FUSION PROTEINS
US9676845B2 (en) * 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
EP2295068A1 (en) 2009-09-04 2011-03-16 Neurotune AG Modified agrin-fragment capable of restoring muscle strength for use as a medicament
US8710016B2 (en) 2009-11-17 2014-04-29 Acceleron Pharma, Inc. ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy

Also Published As

Publication number Publication date
CN110036024A (zh) 2019-07-19
AU2017367277A1 (en) 2019-07-04
JP2023116479A (ja) 2023-08-22
KR20190085132A (ko) 2019-07-17
NZ754625A (en) 2023-03-31
CN110036024B (zh) 2024-05-07
ZA201903261B (en) 2020-02-26
CA3045245A1 (en) 2018-06-07
AU2017367277B2 (en) 2021-04-01
US20210253654A1 (en) 2021-08-19
US11407799B2 (en) 2022-08-09
KR102622245B1 (ko) 2024-01-05
JP2019536818A (ja) 2019-12-19
EP3548509A1 (en) 2019-10-09
JP7683901B2 (ja) 2025-05-27
WO2018100483A1 (en) 2018-06-07

Similar Documents

Publication Publication Date Title
IL261175B (en) Propyne-indole compounds
GB201610147D0 (en) Novel compounds
GB201604647D0 (en) Novel compounds
GB201604638D0 (en) Novel compounds
GB201602854D0 (en) Novel compounds
GB201603779D0 (en) Novel compounds
GB201602934D0 (en) Compounds
GB201620119D0 (en) Compounds
GB201619694D0 (en) Compounds
GB201604020D0 (en) Compounds
GB201604027D0 (en) Compounds
SI3464336T1 (sl) Spojine
GB201610854D0 (en) Compounds
IL263228A (en) Benzoxaborole compounds
GB201608777D0 (en) Compounds
GB201613946D0 (en) Compounds
GB201604022D0 (en) Compounds
GB201604030D0 (en) Compounds
GB201621520D0 (en) Compounds
GB201713217D0 (en) Compounds
GB201622362D0 (en) Compounds
GB201604029D0 (en) Compounds
GB201601301D0 (en) Novel compounds
GB201622365D0 (en) Compounds
GB201604031D0 (en) Compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)